Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)

BACKGROUND: Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). OBJECTIVES: The aim of this study was to evaluate the safety, effectiveness, and pharmacokinetics (PK) of crisaborole in infants aged 3 to < 24 month...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlessinger, Joel, Shepard, Julie S., Gower, Richard, Su, John C., Lynde, Charles, Cha, Amy, Ports, William C., Purohit, Vivek, Takiya, Liza, Werth, John L., Zang, Chuanbo, Vlahos, Bonnie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125059/
https://www.ncbi.nlm.nih.gov/pubmed/32212104
http://dx.doi.org/10.1007/s40257-020-00510-6

Ejemplares similares

Ejemplares similares